Johnson & Johnson's Strategic Pivot: Axing Two Failed Drug Candidates and Doubling Down on Neuroscience and Cell Therapy with $10 Billion Bet

Mar 15, 2025 07:31 CST Updated 07:31

Johnson & Johnson

Medical Device R&D and Manufacturer

Source: PharmaBlock

Author:Pharmadeep Editor: Vitality Haha

In March 2025, Johnson & Johnson terminated the development of two major new drugs within a week, causing a stir in the industry. On one hand, it’s about decisive loss-cutting; on the other hand, it’s about strategic focus. What kind of game is this healthcare giant playing? This article analyzes clinical data and business layout to interpret the deep transformation of Johnson & Johnson's commercial logic.

01.

Double Inquiry into Efficacy and Safety

The Inevitability of Two New Drugs' Failure

1. GEN3014: CD38 Antibody Upgrade Encounters "Safety Waterloo"

GEN3014, as the second-generation CD38 monoclonal antibody co-developed by Johnson & Johnson and Genmab, was once regarded as the iterative product of daratumumab, the star drug for multiple myeloma. However, data from Phase I/II clinical trials showed:

Overall Response Rate (ORR) 55%, showing no significant advantage over daratumumab (52%);
The incidence of Grade 3 or higher TEAEs was as high as 73.3%.Far exceeding daratumumab's 18.6%;
The proportion of treatment discontinuation due to side effects reached 51.1%, highlighting commercialization risks.

Johnson & Johnson's decision to abandon the exercise of rights is essentially a rational response to the "lack of efficacy breakthrough + safety shortcomings," and also reflects the survival rules under the intense competition of the CD38 target (such as Sanofi's isatuximab).

2. Aticaprant: The Chain Reaction of "Insufficient Efficacy" in the Depression Field

As a κ-opioid receptor antagonist, Aticaprant was once highly anticipated by Johnson & Johnson, with predicted peak sales of $1 billion to $5 billion. However, phase III data from the VENTURA program showed:

When combined with existing therapies, it failed to significantly improve depressive symptoms in patients;
The concurrent failure of Neumora's navacaprant (a drug in the same class) has led to a "mechanism质疑" effect.

Despite Johnson & Johnson's retention of its safety advantages and plans to explore other indications, the short-term setback for its depression pipeline is a foregone conclusion.

02.

Strategic Contraction and Expansion

Johnson & Johnson's "Addition and Subtraction" Logic

1. Neuroscience: Acquisition and Pipeline Focus

$14.6 Billion Acquisition of Intra-Cellular Therapies: Obtaining Caplyta, a Phase III Successful Drug for Treating Major Depressive Disorder, Fills the Gap Left by Aticaprant;
Seltorexant and Spravato Advance on Two Fronts: The former targets orexin-2 receptors for treating insomnia-related depression, while the latter, as an NMDA receptor antagonist nasal spray, has already surpassed $1 billion in sales in 2024.
China’s Esketamine Launch: Leveraging the Spravato Technology Platform to Rapidly Capture the Acute Suicidal Depression Market.

2. Oncology Field: Dual Engines of Cell Therapy and Digital Orthopedics

Global Expansion of CAR-T Therapy: Multiple Myeloma Treatment Now Covers the United States, Germany, Switzerland, the United Kingdom, Brazil, and Other Countries, with Over 5,000 Patients Treated; Scale-Up Planned Within the Next 12-18 Months.
Orthopedic Robots Gain Momentum: VELYS™ Robotic-Assisted Solution Has Been Implemented in Over 100,000 Knee Replacement Surgeries Across 31 Global Markets; KINCISE 2 Surgical Automation System Accelerates Penetration into Grassroots Markets.
Acceleration in Solid Tumor Strategy: CAR-T Technology Expands Beyond Hematological Malignancies like DLBCL, Aiming to Cover Patients with "No Available Treatment" for Solid Tumors.

03.

Strategic Insights Behind the Data

Johnson & Johnson's Three Core Logics

1. LinBed Value Priority:The termination of GEN3014 and Aticaprant reflects Johnson & Johnson's stringent demand for "differentiated efficacy." Even with a novel mechanism (e.g., κ-opioid receptor antagonism), if it cannot surpass existing therapies, they decisively abandon it.

2. Risk ScoreDispersion and Pipeline Collaboration:By acquiring (e.g., Intra-Cellular) and reusing technology platforms (e.g., NMDA receptor antagonist-derived Esketamine), the impact of a single pipeline failure on the overall business is reduced.

3. GlobalizationEmphasizing Localization Equally:

China Market Undergoes Deep Adjustment: Surgical Division Reorganized, Production Capacity Doubled (Shanghai Solid Dosage Line Reaches 2 Billion Tablets/Year), Strengthening "Made in China" Output;
Democratization of Cell Therapy: Reducing CAR-T Treatment Costs through Collaborative Manufacturing and Logistics Optimization (e.g., Germany, Brazil bases).

Conclusion

Johnson & Johnson's "strategic divestiture" is no accident. From neuroscience to cell therapy, from China's production capacity to the global supply chain, its strategy has always revolved around the dual core of "clinical value + commercial efficiency." In 2024, Johnson & Johnson topped the list of global MNCs with a total revenue of $88.8 billion. Whether it can achieve breakthroughs in fields such as neurodegenerative diseases and solid tumor CAR-T will determine whether it can maintain its position among the top three global pharmaceutical companies.

Data source: Johnson & Johnson financial reports, clinical study disclosures, and company announcements.